Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

168.83 +4.15 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
News headline image
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns
Boston, MA – October 1, 2025 – Biogen Inc. (NASDAQ: BIIB) saw its stock surge by an impressive 9.02% today, propelled by a wave of promising advancements in its Alzheimer's disease drug testing... 
Via MarketMinute
News headline image
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years ↗
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs. 
Via Benzinga
Topics Government
News headline image
Wednesday's session: top gainers and losers in the S&P500 index ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
A Look Into Biogen Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Dow Futures Defy Shutdown Fears: A Deep Dive into Market Resilience
As the U.S. government teeters on the brink of another shutdown, a seemingly counter-intuitive phenomenon is gripping financial markets: Dow futures are not only holding steady but are showing signs of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29,... 
Via MarketMinute
Topics Artificial Intelligence Earnings
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗
Via Stocktwits
Topics Government
News headline image
Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy ↗
On Tuesday, the U.S. 
Via Benzinga
News headline image
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Biogen ↗
 
Via Benzinga
News headline image
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment ↗
Biogen will integrate Alcyone's team and divest the remaining assets into Neela Therapeutics as part of its $85 million acquisition. 
Via Benzinga
News headline image
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
News headline image
Biogen (BIIB) Stock Trades Down, Here Is Why
Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Beyond The Numbers: 10 Analysts Discuss Biogen Stock ↗
 
Via Benzinga
News headline image
Market Monitor News September 3 BMO - Tech Slammed, Yields Spike, Trump Stirring the Pot Again ↗
Wall Street kicked off September on shaky ground as rising bond yields pressured tech stocks and legal turmoil over Trump’s tariffs added fresh uncertainty. Meanwhile, investors brace for Friday’s key... 
Via Chartmill
Topics Bonds Economy Government
News headline image
Biogen (BIIB) Stock Is Up, What You Need To Know
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their... 
Via StockStory
Topics Economy
News headline image
Tuesday's session: top gainers and losers in the S&P500 index ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
VIX Jumps 20% As Stocks Slump, Gold Tops Record Highs: What's Moving Markets Tuesday? ↗
Wall Street stumbled on Tuesday, with broad losses by midday in New York as investors turned risk-off amid mounting concerns over lofty valuations, seasonal headwinds and fiscal strains. 
Via Benzinga
Topics Stocks
News headline image
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
News headline image
3 Mid-Cap Stocks That Concern Us
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment ↗
This could put pressure on Eli Lilly, which sells a competing drug called Kisunla. 
Via Investor's Business Daily
News headline image
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.